AstraZeneca, Argenx Score Phase III Wins in Autoimmune Space
Two biologic therapeutic candidates have met their primary endpoints in phase III trials, including AstraZeneca’s Champion-NMOSD trial and Argenx’s Advance trial.
Source: biospace.com
Soliris Prevent News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Soliris Prevent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.